One cupcake won't kill you', 'I'm going to get diabetes just looking at that', 'That person doesn't look like they have ...

Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...

Abbott (NYSE:ABT) is launching a new initiative that takes a look at some of the stigmas and stereotypes that come with ...

Abbott has launched Above the Bias, a global initiative to drive awareness about the health impact that common misconceptions and bias about diabetes can have on people living with ...

The CGM business is among the top growth drivers in Abbott’s medical devices business, with diabetes care posting 19% organic sales growth for the first nine months of 2024, Abbott said in a ...

The FreeStyle Libre 3 system helped Nathan manage his diabetes. Now, he's sharing his story to help lift stigma.Abbott NORTHAMPTON, MA / ACCESS Newswire / February 7, 2025 / As a competitive powerlift ...

Abbott Laboratories on Wednesday forecast annual profit in line with Wall Street estimates, as it expects elevated medtech-related procedures to boost demand for its devices, including ...

The Medical (TASE:PMCN) Device segment, in particular, exhibited robust growth, with standout performances in the Structural Heart and Diabetes care units. Looking ahead to 2025, Abbott has ...

Investors feel optimistic about Abbott's robust strength in the Core Diagnostics business. Yet, unfavorable forex impacts are concerning.

Stifel analyst Rick Wise has a positive outlook on Abbott’s Q4 2024 results and its 2025 projections. He sees strong momentum in the Diabetes Care and Structural Heart segments, which are ...